SAN JOSE, Calif. - Anixa Biosciences, Inc. (NASDAQ: NASDAQ:ANIX), a clinical-stage biotechnology company valued at $77.6 million, recently shared updates on its cancer treatment programs, including ...
Despite a big increase in “watchful waiting” in the past 15 years, there’s a new study from the U.S. Department of Veterans Affairs health system shows that overtreatment of prostate cancer persists.